Benitec Biopharma (BNTC) said Tuesday it has priced an offering of about 1.4 million shares or pre-funded warrants and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital at $13.00 per share and $12.9999 per warrant.
The pre-funded warrants will be immediately exercisable, the company said.
The offerings are expected to close on Wednesday, the company said.
Gross proceeds to Benitec from the offerings are expected to be approximately $30 million, the company said.
The company said it intends to use the net proceeds, together with existing cash on hand, to finance continued development of its drug candidates and other general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。